Driving Efficiency: Leveraging Model‐Informed Approaches in 505(b)(2) Regulatory Actions
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.6109 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Vishnu Dutt Sharma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver S…. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduced by the Hatch‐Waxman Amendments of 1984, 505(b)(2) applications permit the US Food and Drug Administration to rely, for approval of a new drug application, on information from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. This pathway is designed to circumvent the unnecessary duplication of studies already conducted on a previously approved drug. It can lead to a considerably more efficient and expedited route to approval compared to a traditional development path. Model‐informed drug development refers to the utilization of a diverse array of quantitative models in drug development to streamline the decision‐making process. In this approach, diverse quantitative models that integrate knowledge of physiology, disease processes, and drug pharmacology are employed to address drug development challenges and guide regulatory decisions. Integration of these model‐informed approaches into 505(b)(2) regulatory submissions and decision‐making can further expedite the approval of new drugs. This article discusses some applications of model‐informed approaches that were used to support 505(b)(2) drug development and regulatory actions. Specifically, various quantitative models such as population pharmacokinetic and exposure‐response models have been employed to provide evidence of effectiveness, guide dosing in subgroups such as subjects with hepatic or renal impairment, and inform policies. These case study examples collectively underscore the significance of model‐informed approaches in drug development and regulatory decisions associated with 505(b)(2) submissions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
- Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Zitieren
APA
Sharma, V. D., Bhattaram, V. A., Krudys, K., Li, Z., Marathe, A., Mehrotra, N., Wang, X., Liu, J., Stier, E., Florian, J., Madabushi, R., & Zhu, H. (2024). Driving Efficiency: Leveraging Model‐Informed Approaches in 505(b)(2) Regulatory Actions. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6109
Vancouver
Sharma VD, Bhattaram VA, Krudys K, Li Z, Marathe A, Mehrotra N, et al. Driving Efficiency: Leveraging Model‐Informed Approaches in 505(b)(2) Regulatory Actions. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.6109
BibTeX
@article{Sharma2024,
author = {Sharma, Vishnu Dutt and Bhattaram, Venkatesh Atul and Krudys, Kevin and Li, Zhihua and Marathe, Anshu and Mehrotra, Nitin and Wang, Xiaofeng and Liu, Jiang and Stier, Ethan and Florian, Jeffry and Madabushi, Raj and Zhu, Hao},
title = {Driving Efficiency: Leveraging Model‐Informed Approaches in 505(b)(2) Regulatory Actions},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.6109}
}
EUVIMED